Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $12.70 to $13.61
• 50-Day Range: $9.37 to $16.55
• 52-Week Range: $8.91 to $28.09
• Volume: 729,786 shs
• Average Volume: 487,077 shs
• Market Capitalization: $703.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.43
• Consensus Rating: Moderate Buy

Bicara Therapeutics Stock Analysis - MarketRank™

Bicara Therapeutics scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bicara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Bicara Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BCAX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicara Therapeutics does not currently pay a dividend.

Dividend Growth

Bicara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BCAX.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.32

News Sentiment

Bicara Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

2 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

BCAX Stock Analysis - Frequently Asked Questions

How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $17.42 at the beginning of 2025. Since then, BCAX shares have decreased by 25.9% and is now trading at $12.90.
View the best growth stocks for 2025 here.

How were Bicara Therapeutics' earnings last quarter?

Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its quarterly earnings results on Thursday, March, 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.08.

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an IPO on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share.

When did Bicara Therapeutics' lock-up period expire?

Bicara Therapeutics' lock-up period expired on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

Who are Bicara Therapeutics' major shareholders?

Top institutional shareholders of Bicara Therapeutics include Charles Schwab Investment Management Inc. (0.28%), TD Asset Management Inc (0.24%), Atle Fund Management AB (0.22%) and Deutsche Bank AG (0.20%).
View institutional ownership trends.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/27/2025
• Today: 5/09/2025
• Next Earnings (Estimated): 6/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.43
• High Stock Price Target: $48.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +151.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 54,536,000
• Free Float: N/A
• Market Cap: $703.51 million
• Optionable: N/A
• Beta: N/A